| Abstrakt: |
Introduction: In spite of the improvements in developing antiretroviral treatments, there are no approved HIV vaccines. To achieve an effective vaccine against HIV-1 requires induction of strong humoral and cellular immune responses, so developing an effectual vaccine is required. The aim of this study was the immunological assessment of HIV-1 Nef-MPER-V3 harboring LDP12 penetrating peptide in BALB/c mice in order to induce effective immune responses. Materials & Methods: In the current study, presenting 55 female mice were utilized for immunization with LDP12-Nef- MPER-V3. The mice were divided into 11 groups with 5 mice each group. Immunizations were performed three times at three week intervals and subcutaneously in a volume of 100 μl per mouse. Two weeks after final injection, humoral and cellular immune responses were evaluated in blood serum and splenocytes respectively, by using ELISA method. Finally, the data analysis was performed, using Mann-Whitney u test. Results: Although the level of total antibody production was observed in all main groups with different titrations, but the antibody level was higher in the mice groups that injected with the LDP12 antigen with adjuvants immunity than in the control group (p=0.045). Also, IgG2a was the predominant isotype (Th1-biased response) in mice immunized group that had LDP12 antigen with Hsp27 adjuvant. Conclusion: The data indicated that the high immune system stimulating capabilities of LDP12-Nef-MPER-V3 injection regime accompanied by Hp91 adjuvant, which provides the potential for an efficient HIV vaccine. [ABSTRACT FROM AUTHOR] |
